Non-Clinical Safety Evaluation of Exosomes Derived from Human Umbilical Cord Mesenchymal Stem Cells in Cynomolgus Monkeys
Xin-Mei Hu,Can-Can Wang,Yu Xiao,Yu Liu,Hong-Ri Huang,Peng Jiang,Ying-Kai Wang,Yun-Jin Lin,Liang-Cheng Li,Zhong-Quan Qi
DOI: https://doi.org/10.2147/ijn.s454438
IF: 7.033
2024-05-28
International Journal of Nanomedicine
Abstract:Xin-Mei Hu, 1, &ast Can-Can Wang, 1, &ast Yu Xiao, 1 Yu Liu, 1 Hong-Ri Huang, 2 Peng Jiang, 1 Ying-Kai Wang, 1 Yun-Jin Lin, 1 Liang-Cheng Li, 3 Zhong-Quan Qi 1 1 Medical College, Guangxi University, Nanning, Guangxi Zhuang Autonomous Region, People's Republic of China; 2 Department of Research and Development, Guangxi Taimei Rensheng Biotechnology Co., Ltd, Nanning, Guangxi Zhuang Autonomous Region, People's Republic of China; 3 School of Pharmaceutical Sciences, Xiamen University, Xiamen, Fujian Province, People's Republic of China &astThese authors contributed equally to this work Correspondence: Zhong-Quan Qi, Guangxi University, Da-Xue-Dong Road No. 100, Xixiangtang District, Nanning, Guangxi Zhuang Autonomous Region, 530004, People's Republic of China, Tel +8613806001271, Email Liang-Cheng Li, Xiamen University, No. 4221-115, Rm 355, Xiang'an District, Xiang'an, Xiamen Fujian Province, 361102, People's Republic of China, Tel +8618359206906, Email Purpose: In recent years, exosomes have been proved to be used to treat many diseases. However, due to the lack of uniform quality control standards for exosomes, the safety of exosomes is still a problem to be solved, especially now more and more exosomes are used in clinical trials, and its non-clinical safety evaluation is particularly important. However, there is no safety evaluation standard for exosomes at present. Therefore, this study will refer to the evaluation criteria of therapeutic biological products, adopt non-human primates to evaluate the non-clinical safety of human umbilical cord mesenchymal stem cell exosomes from the general pharmacology and immunotoxicity, aiming at establishing a safety evaluation system of exosomes and providing reference for the clinical application of exosomes in the future. Methods: 3.85 × 10 12 exosomes derived from human umbilical cord mesenchymal stem cells were injected into cynomolgus monkeys intravenously. The changes of general clinical conditions, hematology, immunoglobulin, Th1/Th2 cytokines, T lymphocytes and B lymphocytes, and immune organs were observed before and within 14 days after injection. Results: The results showed that exosomes did not have obvious pathological effects on the general clinical conditions, blood, coagulation function, organ coefficient, immunoglobulin, Th1/Th2 cytokines, lymphocytes, major organs, and major immune organs (spleen, thymus, bone marrow) of cynomolgus monkeys. However, the number of granulocyte-macrophage colonies in exosomes group was significantly higher than that in control group. Conclusion: To sum up, the general pharmacological results and immunotoxicity results showed that the injection of 3.85 × 10 12 exosomes may have no obvious adverse reactions to cynomolgus monkeys. This dose of exosomes is relatively safe for treatment, which provides basis research for non-clinical safety evaluation of exosomes and provides reliable research basis for future clinical application of exosomes. Keywords: exosomes, cynomolgus monkeys, safety, immunotoxicity Exosomes are tiny, membranous vesicles with a diameter of approximately 30–150 nm. Exosomes are surrounded by a lipid bilayer, secreted by most cells, and widely distributed in various body fluids, including serum, plasma, saliva, urine, cerebrospinal fluid, and emulsions. They are involved in physiological and pathological processes and the development of many diseases. 1,2 Exosomes derived from human umbilical cord mesenchymal stem cells (HUCMSCs) have the potential to treat kidney, liver, ocular, spinal cord, and neurodegenerative diseases. However, with the increasing application of exosomes in disease treatment, safety issues need to be paid attention to. At present, there are few studies on the safety of exosomes. Some studies have suggested that the extracellular vesicles derived from mesenchymal stem cells have complex components and may contain potential therapeutic components, such as toxic proteins and harmful miRNAs, and there is a lack of large-scale and multi-center clinical trials to confirm the effectiveness and safety of extracellular vesicles. 3 Another study also shows that the safety of exosomes is still an unsolved problem, and further research in this field, such as clinical research or research using large animal models, still needs to prove the safety of exosomes in treatment, especially the safety of exosomes secreted by cancer cells. 4 In addition, as the carrier or therapeutic segment of drug delivery, it is necessary to conduct preclinical tests before clinical application. First of all, exo -Abstract Truncated-
pharmacology & pharmacy,nanoscience & nanotechnology